Table 2.
The SUCRA values for each treatment
| Treatment | AEs | Rank | SAEs | Rank | MG-ADL | Rank | QMG | Rank | MGC | Rank | MG-QoL 15r | Rank |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Batoclimab | 49.86% | 7 | 72.27% | 3 | 78.02% | 3 | 99.66% | 1 | 92.48% | 1 | 72.04% | 2 |
| Efgartigimod | 73.25% | 3 | 61.25% | 5 | 25.49% | 12 | 48.68% | 7 | 24.96% | 8 | 49.45% | 5 |
| Nipocalimab | 42.62% | 8 | 89.08% | 1 | 47.03% | 8 | 13.18% | 13 | - | - | 35.30% | 8 |
| Rozanolixizumab | 19.99% | 13 | 6.52% | 13 | 84.53% | 1 | 79.34% | 2 | 85.40% | 2 | - | - |
| Ravulizumab | 32.32% | 11 | 16.91% | 12 | 66.43% | 5 | 54.43% | 5 | - | - | 41.25% | 6 |
| Eculizumab | - | - | 70.93% | 4 | 68.95% | 4 | 74.84% | 3 | 64.02% | 3 | 96.66% | 1 |
| Zilucoplan | 28.97% | 12 | 42.62% | 9 | 81.61% | 2 | 74.55% | 4 | 61.40% | 5 | 66.98% | 3 |
| Iscalimab | 74.64% | 2 | 54.99% | 6 | 50.87% | 7 | 34.89% | 11 | 41.33% | 6 | 56.20% | 4 |
| Belimumab | 84.85% | 1 | 85.30% | 2 | 21.03% | 13 | 49.84% | 6 | 15.34% | 9 | - | - |
| Rituximab | 35.30% | 10 | 49.32% | 7 | 38.86% | 10 | 48.60% | 8 | 39.57% | 7 | 36.49% | 7 |
| Tacrolimus | 39.49% | 9 | 42.86% | 8 | 44.60% | 9 | 39.53% | 10 | - | - | - | - |
| Placebo | 55.23% | 5 | 37.05% | 10 | 6.65% | 14 | 7.41% | 14 | 11.53% | 10 | 11.78% | 10 |
| Methotrexate | 50.75% | 6 | - | - | 57.11% | 6 | 46.96% | 9 | 63.96% | 4 | 34.86% | 9 |
| Mycophenolate Mofetil | 65.74% | 4 | 20.92% | 11 | 28.82% | 11 | 28.09% | 12 | - | - | - | - |
AEs, adverse events; SAEs, severe adverse events; MG-ADL, Myasthenia Gravis Activities of Daily Living; QMG, Quantitative Myasthenia Gravis; MGC, Myasthenia Gravis
Composite; MG-QoL 15r,15-item revised version of the Myasthenia Gravis Quality of Life